BioCentury
ARTICLE | Finance

With biggest biotech SPAC merger yet, Cerevel’s public path could augur more deals in same vein

For Tony Coles’ neuroscience company, the deal effectively replaces a more traditional path to going public

July 30, 2020 11:08 AM UTC

Cerevel’s path to NASDAQ via a SPAC is likely to presage similar deals for other life sciences companies.

Biotechs and investors have increasingly made use this year of special purpose acquisition companies, which are blank-check shell companies that are set up to merge with private companies after themselves going public...